Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut‐Offs to Use?
Canadian Journal of Gastroenterology and Hepatology · 2021-01 · 2021 (1)
DOI: 10.1155/2021/6662760 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Gastroenterology and Hepatology, online erschienen am 26.03.2021. Verfasst von Roxana Sirli und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Advanced Regional Research Center in Gastroenterology and Hepatology, "Victor Babeş" University of Med…. Hauptthemen laut MEDLINE: Elasticity Imaging Techniques, Non-alcoholic Fatty Liver Disease. Die Arbeit wurde bisher 64-mal zitiert (Crossref) und nennt 53 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: “Victor Babeş” University of Medicine, Pharmacy Timişoara-Acronim: BRLIV.
Abstract (Originalsprache)
Chronic liver diseases (CLDs) are a public health problem, even if frequently they are underdiagnosed. Hepatic steatosis (HS), encountered not only in nonalcoholic fatty liver disease (NAFLD) but also in chronic viral hepatitis, alcoholic liver disease, etc., plays an important role in fibrosis progression, regardless of CLD etiology; thus, detection and quantification of HS are imperative. Controlled attenuation parameter (CAP) feature, implemented in the FibroScan® device, measures the attenuation of the US beam as it passes through the liver. It is a noninvasive technique, feasible and well accepted by patients, with lower costs than other diagnostic techniques, with acceptable accuracy for HS quantification. Multiple studies have been published regarding CAP performance to quantify steatosis, but due to the heterogeneity of CLD etiologies, of steatosis prevalence, etc., it had widely variable calculated cut‐off values, which in turn limited the day‐to‐day utility of CAP measurements in clinical practice. This paper reviews published studies trying to suggest cut‐off values usable in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Department of Gastroenterology and Hepatology, Advanced Regional Research Center in Gastroenterology and Hepatology, "Victor Babeş" University of Medicine and Pharmacy, 156, Liviu Rebreanu Bv., Timişoara 300723, Romania.
ORCID-Profile: Roxana Sirli, Ioan Sporea
Förderung
- “Victor Babeş” University of Medicine
- Pharmacy Timişoara-Acronim: BRLIV
Zitieren
APA
Sirli, R., & Sporea, I. (2021). Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut‐Offs to Use?. Canadian Journal of Gastroenterology and Hepatology, 2021(1). https://doi.org/10.1155/2021/6662760
Vancouver
Sirli R, Sporea I. Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut‐Offs to Use?. Canadian Journal of Gastroenterology and Hepatology. 2021;2021(1). doi:10.1155/2021/6662760
BibTeX
@article{Sirli2021,
author = {Sirli, Roxana and Sporea, Ioan},
title = {Controlled Attenuation Parameter for Quantification of Steatosis: Which Cut‐Offs to Use?},
journal = {Canadian Journal of Gastroenterology and Hepatology},
year = {2021},
volume = {2021},
number = {1},
doi = {10.1155/2021/6662760}
}
EUVIMED